Dr. Geoffrey Shouse, DO, PhD

Dr. Shouse practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Shouse's NPI, 1568721116, was assigned on May 15, 2012. Dr. Shouse graduated from WesternU College of Osteopathic Medicine of the Pacific in 2012. Dr. Shouse holds California license 20A13053.

Dr. Shouse's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Shouse's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. The medical group on file is City of Hope. Dmand AI also links Dr. Shouse to 1 more other site, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shouse practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Shouse's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Shouse is board certified in hematology by the American Board of Internal Medicine. Dr. Shouse is licensed in California.

Dmand AI lists chronic anemia, chronic leukemia, immune deficiency disease, lymphoma and multiple myeloma among the conditions Dr. Shouse treats.

CMS data shows 1,366 Medicare services from Dr. Shouse across 11 procedure codes in 2024, for 251 Medicare patients. Medicare paid $115,982 for them.

CMS counts 251 Medicare patients who saw Dr. Shouse in 2024. The largest group is 65 to 74, with 124 patients. 70% of them have high cholesterol, and 69% have high blood pressure. 30% are also on Medicaid. Their average risk score is 3.05, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shouse's median patient age at 67, with 44% women.

In 2024, Dr. Shouse wrote 467 Medicare Part D claims for 83 patients. 87% of them were for generic drugs. CMS names the drug for 269 of them, across 10 drugs with 11 or more claims each, at $253,257 in total drug cost. In 2023, CMS named 256 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Shouse for performance year 2024, reported as part of a group. Dr. Shouse accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Shouse as offering telehealth.

Dmand AI links 51 papers to Dr. Shouse, published from 2016 to 2025. 2023 was the busiest year, with 8. The most frequent topics are Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse and Receptors, Chimeric Antigen. Dr. Shouse has published most often in Blood Adv. Dr. Shouse's most frequent co-authors are Alex F. Herrera, MD, Reem Md Karmali, MD and Stephen J. Forman, MD.

Dmand AI links Dr. Shouse to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Hodgkin Disease, Leukemia, Prolymphocytic, T-Cell and Leukemia, Prolymphocytic.

CMS Open Payments shows 145 general payments to Dr. Shouse from 20 drug and device companies from 2017 to 2025. Speaker and faculty fees make up the largest share, 64% of the total. Kite Pharma, Inc. paid the most, $74,397.

Dmand AI lists 1 award for Dr. Shouse, most recently ASH Clinical Research Training Award in 2022.

Dr. Shouse graduated from WesternU College of Osteopathic Medicine of the Pacific in 2012. Dr. Shouse is a member of AOA.

Dr. Shouse is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.